Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1176
1. Kano Y, Björne J, Ginter F, Salakoski T, Buyko E, Hahn U, Cohen KB, Verspoor K, Roeder C, Hunter LE, Kilicoglu H, Bergler S, Van Landeghem S, Van Parys T, Van de Peer Y, Miwa M, Ananiadou S, Neves M, Pascual-Montano A, Özgür A, Radev DR, Riedel S, Sætre R, Chun HW, Kim JD, Pyysalo S, Ohta T, Tsujii J: U-Compare bio-event meta-service: compatible BioNLP event extraction services. BMC Bioinformatics; 2011 Dec 18;12:481
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U-Compare bio-event meta-service: compatible BioNLP event extraction services.
  • BACKGROUND: Bio-molecular event extraction from literature is recognized as an important task of bio text mining and, as such, many relevant systems have been developed and made available during the last decade.
  • While such systems provide useful services individually, there is a need for a meta-service to enable comparison and ensemble of such services, offering optimal solutions for various purposes.
  • RESULTS: We have integrated nine event extraction systems in the U-Compare framework, making them intercompatible and interoperable with other U-Compare components.
  • The U-Compare event meta-service provides various meta-level features for comparison and ensemble of multiple event extraction systems.
  • Experimental results show that the performance improvements achieved by the ensemble are significant.
  • CONCLUSIONS: While individual event extraction systems themselves provide useful features for bio text mining, the U-Compare meta-service is expected to improve the accessibility to the individual systems, and to enable meta-level uses over multiple event extraction systems such as comparison and ensemble.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Bioinformatics. 2007;8:50 [17291334.001]
  • [Cites] BMC Bioinformatics. 2008;9:10 [18182099.001]
  • [Cites] BMC Bioinformatics. 2008;9:78 [18237434.001]
  • [Cites] Genome Biol. 2008;9 Suppl 2:S4 [18834495.001]
  • [Cites] Genome Biol. 2008;9 Suppl 2:S6 [18834497.001]
  • [Cites] Bioinformatics. 2009 Mar 15;25(6):815-21 [19188193.001]
  • [Cites] Bioinformatics. 2009 Aug 1;25(15):1997-8 [19414535.001]
  • [Cites] J Bioinform Comput Biol. 2010 Feb;8(1):131-46 [20183879.001]
  • [Cites] IEEE/ACM Trans Comput Biol Bioinform. 2010 Jul-Sep;7(3):385-99 [20704011.001]
  • (PMID = 22177292.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01GM083649; United States / NLM NIH HHS / LM / R01LM009254; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/G013160/1; United States / NLM NIH HHS / LM / R01LM008111; United States / NIDA NIH HHS / DA / U54 DA021519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3299809
  •  go-up   go-down


2. Akamatsu K, Miyauchi S, Ohshima K, Okita S, Yasuhara Y, Mogami H, Ohta Y, Hamamoto K: Alleviation of gallbladder complications by treatment of hepatic arterial embolization with caerulein. Cancer Chemother Pharmacol; 1989;23 Suppl:S59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleviation of gallbladder complications by treatment of hepatic arterial embolization with caerulein.
  • Transcatheter arterial embolization (TAE) with the concurrent use of caerulein was assessed for the purpose of preventing gallbladder complications often seen after TAE of hepatic carcinoma.
  • Ninety-six cases with primary hepatic carcinoma, who had undergone TAE in the right hepatic arterial region over the past 4 years, were divided into three groups: 22 cases for which embolization was possible on a selective basis by passing the catheter to the peripheral side beyond the bifurcated region of the cystic artery; 40 cases who had undergone TAE in which caerulein was not administered, from the central side of the bifurcated region of the cystic artery; and 34 cases given 20 micrograms caerulein 15-30 min before TAE.
  • A comparison was made using the abdominal pain, pyrexia, rate of leukocytosis and the US findings of the gallbladder as the indices of the gallbladder complications.
  • As a result, it became evident that it was possible to prevent or alleviate gallbladder complications if caerulein were administered before TAE in cases where the embolizing substances were infused in the right hepatic artery from the central side of the bifurcated region of the cystic artery.
  • It was conclusively shown that the gallbladder blood flow decreases if the organ is contracted by caerulein, which in turn causes a decrease in the inflow of the embolizing substances whereby complications are alleviated.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Ceruletide / therapeutic use. Embolization, Therapeutic / adverse effects. Gallbladder / blood supply. Infarction / prevention & control. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cholecystography. Female. Hepatic Artery. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1986 Aug;91(2):313-7 [3087809.001]
  • [Cites] Radiology. 1981 Jul;140(1):51-8 [7244243.001]
  • [Cites] Dig Dis Sci. 1979 Jun;24(6):482-4 [313329.001]
  • [Cites] AJR Am J Roentgenol. 1985 Jan;144(1):135-8 [2981123.001]
  • [Cites] World J Surg. 1982 May;6(3):352-7 [7113240.001]
  • [Cites] Radiology. 1984 May;151(2):371-5 [6709905.001]
  • [Cites] Radiology. 1983 Oct;149(1):85-9 [6310685.001]
  • (PMID = 2538268.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 888Y08971B / Ceruletide
  •  go-up   go-down


3. Hamamoto K, Ohno T, Ogawa H: [Myelodysplastic syndrome with CREST syndrome successfully treated with metenolone--A case report]. Rinsho Ketsueki; 1996 Apr;37(4):362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myelodysplastic syndrome with CREST syndrome successfully treated with metenolone--A case report].
  • A 54-year-old woman was diagnosed as having refractory anemia (RA) with CREST syndrome (incomplete type).
  • She showed Raynaud's phenomenon, sclerodactyly and telangiectasia, but not calcinosis and esophageal dysmotility.
  • Laboratory findings revealed anemia and thrombocytopenia, and myelodysplasia, abnormal karyotype of 47, XX, +8 in bone marrow cells.
  • Antinuclear and centromere antibody was positive.
  • Treatment with prednisolone was not successful.
  • After prednisolone was tapered, she was given 20 mg/body metenolone orally, which led to hematological improvement, and after 6 months of therapy, abnormal karyotype of 47, XX, +8 disappeared.
  • [MeSH-major] Anabolic Agents / therapeutic use. CREST Syndrome / drug therapy. Methenolone / therapeutic use. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Chromosomes, Human, Pair 8. Female. Humans. Karyotyping. Middle Aged. Trisomy


Advertisement
4. Suzuki S, Shinbo K, Takada M, Hamamoto K: [Rehabilitation nursing of patients with ischemic heart disease on an ambulatory basis]. Kangogaku Zasshi; 1985 Aug;49(8):888-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rehabilitation nursing of patients with ischemic heart disease on an ambulatory basis].
  • [MeSH-major] Ambulatory Care. Coronary Disease / rehabilitation
  • [MeSH-minor] Adult. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Heart Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 3850138.001).
  • [ISSN] 0386-9830
  • [Journal-full-title] Kangogaku zasshi
  • [ISO-abbreviation] Kangogaku Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


5. Uchida A, Miwa M, Shinoda H, Koto T, Nagai N, Mochimaru H, Tomita Y, Sasaki M, Ikeda K, Tsubota K, Ozawa Y: Association of Maternal Age to Development and Progression of Retinopathy of Prematurity in Infants of Gestational Age under 33 Weeks. J Ophthalmol; 2014;2014:187929
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Maternal Age to Development and Progression of Retinopathy of Prematurity in Infants of Gestational Age under 33 Weeks.
  • Aim. To find predictive and indicative markers of risk for development of retinopathy of prematurity (ROP) and its progression to the stage requiring laser treatment, in premature infants whose gestational age (GA) was under 33 weeks.
  • Methods. We retrospectively reviewed medical records of 197 premature infants born in 2005-2010 whose GA < 33 weeks and underwent eye screening at Keio University Hospital.
  • The association between candidate risk factors and development or progression of ROP was assessed.
  • Results. Among the 182 eligible infants (median GA, 29.1 weeks; median birth weight (BW), 1028 g), 84 (46%) developed any stage of ROP, of which 45 (25%) required laser treatment.
  • Multivariate analysis using a stepwise method showed that GA (P = 0.002; 95% confidence interval (CI), 0.508-0.858), BW (P < 0.001; 95% CI, 0.994-0.998), and lower maternal age (P = 0.032; 95% CI, 0.819-0.991) were the risk factors for ROP development and GA (P < 0.001; 95% CI, 0.387-0.609) and lower maternal age (P = 0.012; 95% CI, 0.795-0.973) were for laser treatment.
  • The odds ratio of requiring laser treatment was 3.3 when the maternal age was <33 years.
  • Conclusion. ROP was more likely to be developed and progressed in infants born from younger mother and low GA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24876945.001).
  • [ISSN] 2090-004X
  • [Journal-full-title] Journal of ophthalmology
  • [ISO-abbreviation] J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4021680
  •  go-up   go-down


6. Miyagawa M, Kumano S, Sekiya M, Watanabe K, Akutzu H, Imachi T, Tanada S, Hamamoto K: Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease. J Am Coll Cardiol; 1995 Nov 1;26(5):1196-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease.
  • OBJECTIVES: The purpose of this study was to evaluate the feasibility, safety and diagnostic accuracy of thallium-201 myocardial tomography with intravenous adenosine triphosphate (ATP) infusion in patients with suspected coronary artery disease.
  • BACKGROUND: Both ATP and adenosine are potent coronary vasodilators with a very short half-life.
  • Several studies have confirmed that the diagnostic accuracy of adenosine thallium-201 scintigraphy is comparable to that with exercise.
  • However, a high incidence of side effects, including atrioventricular (AV) block, has also been reported.
  • Because the appropriate infusion rate for ATP has not yet been determined, this agent has not been tested in combination with myocardial scintigraphy.
  • METHODS: The study group included 253 consecutive patients who underwent thallium-201 myocardial tomography with ATP infusion (0.16 mg/kg body weight per min for 5 min).
  • The occurrence of adverse effects was carefully monitored.
  • Of the 120 patients with coronary angiography, 76 had significant coronary artery disease.
  • Tomographic images were assessed visually and by computer-quantified polar maps, and they were compared with the results of coronary angiography.
  • RESULTS: Although 56% of the patients had some adverse effects, they were transient and mild.
  • In all patients, the ATP infusion protocol could be completed, and no patient required aminophylline; AV block occurred in only 2% of the patients.
  • The sensitivity and specificity were 88% and 80%, respectively, by visual analysis and 91% and 86%, respectively, by computer quantification.
  • CONCLUSIONS: Thallium tomography with ATP is feasible and has a diagnostic value similar to that with adenosine for detecting coronary artery disease.
  • In addition, it may have fewer side effects than adenosine myocardial tomography.
  • [MeSH-major] Adenosine Triphosphate / administration & dosage. Coronary Disease / radionuclide imaging. Thallium Radioisotopes
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Coronary Angiography. Coronary Vessels / radionuclide imaging. Female. Humans. Injections, Intravenous. Male. Middle Aged. Sensitivity and Specificity. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 7594032.001).
  • [ISSN] 0735-1097
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Thallium Radioisotopes; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


7. Kawamura M, Murase K, Kataoka M, Itoh H, Ishine M, Kawamura S, Nakata S, Hamamoto K: Early and delayed I-123 IMP SPECT in epileptic patients with partial seizures and normal CT. Clin Nucl Med; 1991 Nov;16(11):839-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and delayed I-123 IMP SPECT in epileptic patients with partial seizures and normal CT.
  • Forty-six epileptic patients with partial seizures and normal CT underwent 48 examinations of early and delayed SPECT using I-123 IMP in the interictal phase.
  • One of them underwent a follow-up SPECT in a more stable state compared to the first SPECT.
  • Another patient, with informed consent, underwent a follow-up SPECT in combination with pharmacologic activation with bemegride.
  • Early SPECT was performed 30 minutes after an IMP injection and delayed SPECT 4 to 4 1/2 hours later.
  • Temporal changes in uptake pattern were visually classified into six types and compared with known patterns of SPECT uptake in relation to ischemic, hyperemic, and other changes.
  • These were also correlated with the amount of epileptic activity seen on the EEG.
  • [MeSH-major] Amphetamines. Epilepsies, Partial / radionuclide imaging. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Electroencephalography. Epilepsy, Complex Partial / radiography. Epilepsy, Complex Partial / radionuclide imaging. Female. Humans. Iodine Radioisotopes. Iofetamine. Male. Middle Aged

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1752094.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Amphetamines; 0 / Iodine Radioisotopes; C2A5X08042 / Iofetamine
  •  go-up   go-down


8. Itoh H, Murase K, Hamamoto K: Reflux sign in cholescintigraphy after administration of a gallbladder contracting agent. J Nucl Med; 1989 Jul;30(7):1192-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflux sign in cholescintigraphy after administration of a gallbladder contracting agent.
  • This study reviewed 12 patients with the reflux sign in cholescintigraphy to assess its diagnostic usefulness in evaluating biliary passage.
  • The reflux sign was determined by appearance or increase of the radioactivity in peripheral intrahepatic bile ducts after intramuscular injection of 10 micrograms of ceruletide diethylamine (caerulein).
  • Of the 12 patients, there were common bile duct (CBD) stone in four, chronic pancreatitis in two, biliary dyskinesia in two, papillary adenoma of the CBD, dilated CBD, papillitis, and juxtapapillary duodenal diverticulum in one each.
  • Cholangiographically, dilated caliber of the CBD more than or equal to 12 mm was found in five and equivocal caliber of 8 to 11 mm was in the remaining seven.
  • Apparent stenosis of the CBD was found in four with dilated CBD.
  • There were two patients who had CBD stone with equivocal caliber of the CBD.
  • The reflux sign seems to be a sensitive finding indicating the presence of biliary dysfunction, and would be helpful for the detection of incomplete obstruction of the CBD or CBD stone, especially in a patient with equivocal caliber of the CBD.
  • [MeSH-major] Bile Reflux / radionuclide imaging. Biliary Tract / radionuclide imaging. Biliary Tract Diseases / radionuclide imaging. Gallbladder / drug effects
  • [MeSH-minor] Adult. Aged. Ceruletide / pharmacology. Cholangiography. Cholestasis / etiology. Cholestasis / radiography. Cholestasis / radionuclide imaging. Common Bile Duct / radiography. Common Bile Duct / radionuclide imaging. Common Bile Duct Diseases / complications. Common Bile Duct Diseases / radiography. Common Bile Duct Diseases / radionuclide imaging. Female. Humans. Male. Middle Aged. Muscle Contraction / drug effects. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 1990 Feb;31(2):248-9 [2313367.001]
  • (PMID = 2738700.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 888Y08971B / Ceruletide
  •  go-up   go-down


9. Ninomiya Y, Miwa M, Eda H, Sahara H, Fujimoto K, Ishida M, Umeda I, Yokose K, Ishitsuka H: Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine. Jpn J Cancer Res; 1990 Feb;81(2):188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
  • N4-Trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro 09-1390), a prodrug of the cytostatic 5'-deoxy-5-fluorouridine (5'-DFUR), was synthesized with the aim of reducing of the dose-limiting toxicity of 5'-DFUR, which is diarrhea.
  • In mice bearing Lewis lung carcinoma, 5'-DFUR given po produced a substantial amount of 5-fluorouracil (5-FU) in the intestinal tract as well as tumors, where the enzyme pyrimidine nucleoside phosphorylase, essential for conversion of 5'-DFUR to 5-FU, is predominantly located.
  • With the oral administration of Ro 09-1390 only a small amount of 5-FU was formed in the intestine; however, the administration of Ro 09-1390 and 5'-DFUR at the same dose produced similar amounts of 5-FU in tumor tissues.
  • These differences in metabolism were reflected in their toxicity and antitumor efficacy.
  • The administration of 5'-DFUR resulted in damage to the intestinal mucosal membrane and diarrhea in normal mice, whereas Ro 09-1390 was much less toxic to the intestinal tract.
  • As regards antitumor activity, Ro 09-1390 and 5'-DFUR at equivalent doses inhibited the growth of Lewis lung carcinoma to similar extents.
  • Since Ro 09-1390 was much less toxic to the intestinal tract than 5'-DFUR, mice bearing Lewis lung carcinoma could be given Ro 09-1390 daily over a longer period and at a higher dose, resulting in a longer survival time.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Deoxycytidine / analogs & derivatives. Floxuridine / pharmacology. Intestines / drug effects. Prodrugs / pharmacology
  • [MeSH-minor] Animals. Fluorouracil / metabolism. Fluorouracil / pharmacology. Fluorouracil / toxicity. Male. Mice. Mice, Inbred Strains. Neoplasms, Experimental / drug therapy

  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2139643.001).
  • [ISSN] 0910-5050
  • [Journal-full-title] Japanese journal of cancer research : Gann
  • [ISO-abbreviation] Jpn. J. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Prodrugs; 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; 124012-42-6 / Ro 09-1390; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


10. Matsuzaki H, Fuchigami M, Miwa M: Dietary magnesium supplementation suppresses bone resorption via inhibition of parathyroid hormone secretion in rats fed a high-phosphorus diet. Magnes Res; 2010 Sep;23(3):126-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary magnesium supplementation suppresses bone resorption via inhibition of parathyroid hormone secretion in rats fed a high-phosphorus diet.
  • This study examined the effects of dietary magnesium (Mg) supplementation on bone turnover and serum parathyroid hormone (PTH) levels in rats fed a high-phosphorus (P) diet.
  • Male rats were randomized by weight into three groups, and fed a control diet (control), a high-P diet (HP) or a high-P and high-Mg diet (HPHMg) for 14 days.
  • Serum osteocalcin levels were significantly higher in the HP and HPHMg groups than in the control group.
  • Serum CTx levels were significantly higher in the HP and HPHMg groups than in the control group, while the levels in the HPHMg group were significantly lower than in the HP group.
  • Serum PTH levels were significantly higher in the HP group than in the control and HPHMg groups.
  • Dietary Mg supplementation had a significant influence on serum PTH levels in the HP and HPHMg groups.
  • These results suggest that dietary Mg supplementation suppresses the high bone resorption induced by a high-P diet via inhibition of PTH secretion.
  • Moreover, our results suggest that dietary Mg supplementation may be beneficial for the prevention of bone loss with high-P diet administration.
  • [MeSH-major] Bone Resorption / drug therapy. Parathyroid Hormone / blood. Phosphorus, Dietary / therapeutic use
  • [MeSH-minor] Animals. Dietary Supplements. Eating / drug effects. Magnesium. Male. Osteocalcin / blood. Random Allocation. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20810356.001).
  • [ISSN] 1952-4021
  • [Journal-full-title] Magnesium research
  • [ISO-abbreviation] Magnes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Phosphorus, Dietary; 104982-03-8 / Osteocalcin; I38ZP9992A / Magnesium
  •  go-up   go-down






Advertisement